Limits...
Serological diagnosis of liver metastasis in patients with breast cancer.

Cao R, Wang LP - Cancer Biol Med (2012)

Bottom Line: Alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase (GGT), alkaline phosphatase, lactate dehydrogenase (LDH), and carbohydrate antigen 153 (CA153) levels were significantly higher in patients with liver metastasis than those without liver metastasis.The areas under the curves of LDH, GGT, and CEA were 0.795, 0.784, and 0.661, respectively, and sensitivities of parallel tests for LDH and CA153 and for GGT and CA153 were 88.6% and 85.7%, respectively.The specificity of serial tests for both pairs of enzymes was 97.7%.

View Article: PubMed Central - PubMed

Affiliation: Department of Integrated TCM and Western Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin 30060, China.

ABSTRACT

Objective: To diagnose and explore the serological diagnostic factors for liver metastasis in patients with breast cancer before symptoms occur.

Methods: A total of 430 female in-patients with breast cancer of stages 0 to IIIC who came to Tianjin Medical University Cancer Institute and Hospital from January 2003 to January 2004 were studied and followed up until May 2011. Serum levels of biochemical markers for tumor and liver were measured at the time of diagnosis.

Results: Liver metastasis was more likely to occur in patients with stage III cancer or c-erbB-2-positive expression. Alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase (GGT), alkaline phosphatase, lactate dehydrogenase (LDH), and carbohydrate antigen 153 (CA153) levels were significantly higher in patients with liver metastasis than those without liver metastasis. Diagnostic indices of LDH, GGT, and CA153 were 174 U/L, 32 U/L, and 26.48 µg/L, respectively. The areas under the curves of LDH, GGT, and CEA were 0.795, 0.784, and 0.661, respectively, and sensitivities of parallel tests for LDH and CA153 and for GGT and CA153 were 88.6% and 85.7%, respectively. The specificity of serial tests for both pairs of enzymes was 97.7%.

Conclusions: The sensitivity and specificity of combined tumor and biochemical markers could be used as indicators during screening for breast-liver metastasis.

No MeSH data available.


Related in: MedlinePlus

Survival analysis of breast cancer patients with liver metastasis. (A) Survival time of liver metastasis. (B) Survival time from liver metastasis to death. The median survival time was 54.3 months for patients with liver metastasis, and the median survival time from liver metastasis to death was 11.2 months.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3643646&req=5

f1: Survival analysis of breast cancer patients with liver metastasis. (A) Survival time of liver metastasis. (B) Survival time from liver metastasis to death. The median survival time was 54.3 months for patients with liver metastasis, and the median survival time from liver metastasis to death was 11.2 months.

Mentions: The mean survival times of all patients, patients with liver metastasis, and patients without liver metastasis patients were (92.2±1.7) months, (57.1±3.5) months, and (89.4±1.3) months, respectively. The median survival time was 54.3 months for patients with liver metastasis, and the median survival time from liver metastasis to death was 11.2 months (Figure 1). Cox regression analysis showed that ALB and TB levels and primary tumor and lymph node metastases were significantly correlated with the survival time of breast cancer patients with liver metastasis (P<0.05, Table 2).


Serological diagnosis of liver metastasis in patients with breast cancer.

Cao R, Wang LP - Cancer Biol Med (2012)

Survival analysis of breast cancer patients with liver metastasis. (A) Survival time of liver metastasis. (B) Survival time from liver metastasis to death. The median survival time was 54.3 months for patients with liver metastasis, and the median survival time from liver metastasis to death was 11.2 months.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3643646&req=5

f1: Survival analysis of breast cancer patients with liver metastasis. (A) Survival time of liver metastasis. (B) Survival time from liver metastasis to death. The median survival time was 54.3 months for patients with liver metastasis, and the median survival time from liver metastasis to death was 11.2 months.
Mentions: The mean survival times of all patients, patients with liver metastasis, and patients without liver metastasis patients were (92.2±1.7) months, (57.1±3.5) months, and (89.4±1.3) months, respectively. The median survival time was 54.3 months for patients with liver metastasis, and the median survival time from liver metastasis to death was 11.2 months (Figure 1). Cox regression analysis showed that ALB and TB levels and primary tumor and lymph node metastases were significantly correlated with the survival time of breast cancer patients with liver metastasis (P<0.05, Table 2).

Bottom Line: Alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase (GGT), alkaline phosphatase, lactate dehydrogenase (LDH), and carbohydrate antigen 153 (CA153) levels were significantly higher in patients with liver metastasis than those without liver metastasis.The areas under the curves of LDH, GGT, and CEA were 0.795, 0.784, and 0.661, respectively, and sensitivities of parallel tests for LDH and CA153 and for GGT and CA153 were 88.6% and 85.7%, respectively.The specificity of serial tests for both pairs of enzymes was 97.7%.

View Article: PubMed Central - PubMed

Affiliation: Department of Integrated TCM and Western Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin 30060, China.

ABSTRACT

Objective: To diagnose and explore the serological diagnostic factors for liver metastasis in patients with breast cancer before symptoms occur.

Methods: A total of 430 female in-patients with breast cancer of stages 0 to IIIC who came to Tianjin Medical University Cancer Institute and Hospital from January 2003 to January 2004 were studied and followed up until May 2011. Serum levels of biochemical markers for tumor and liver were measured at the time of diagnosis.

Results: Liver metastasis was more likely to occur in patients with stage III cancer or c-erbB-2-positive expression. Alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase (GGT), alkaline phosphatase, lactate dehydrogenase (LDH), and carbohydrate antigen 153 (CA153) levels were significantly higher in patients with liver metastasis than those without liver metastasis. Diagnostic indices of LDH, GGT, and CA153 were 174 U/L, 32 U/L, and 26.48 µg/L, respectively. The areas under the curves of LDH, GGT, and CEA were 0.795, 0.784, and 0.661, respectively, and sensitivities of parallel tests for LDH and CA153 and for GGT and CA153 were 88.6% and 85.7%, respectively. The specificity of serial tests for both pairs of enzymes was 97.7%.

Conclusions: The sensitivity and specificity of combined tumor and biochemical markers could be used as indicators during screening for breast-liver metastasis.

No MeSH data available.


Related in: MedlinePlus